Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ER genetic test aims to cut repeat trips to hospital

NCT ID NCT06448091

Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving emergency room doctors genetic information about patients can help choose safer medications and reduce return visits. About 1,200 adults aged 40 and older who frequently visit the ER will be randomly assigned to receive genetic testing or usual care. The goal is to see if this approach lowers hospitalizations and ER visits within six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults 40 years or older presenting to a participating ED 2. Receipt of a new order/prescription for a selected PGx medication (Appendix 1), with a duration greater than 7 days, during the current ED visit or within 30 days prior. 3. Documentation of at least 2 prior ED or urgent care visits within the past 12 months Exclusion Criteria: 1. Prior clinical pharmacogenetic test results within the EHR for genes relevant for this study (Appendix 1). 2. History of hepatic or renal transplant 3. History of severe liver disease (stage Child-Pugh C) or renal disease eGFR \<15 ml/min. 4. Any medical condition that would prohibit the ability to complete the study 5. Prisoners, wards of the state, or patients being held under the Baker Act or Marchman Act 6. Life expectancy less than 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pharmacogenomic drug interaction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pharmacogenomic drug interaction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UF Health Emergency Department

    NOT_YET_RECRUITING

    Gainesville, Florida, 32610, United States

  • UF Health Jacksonville Downtown Emergency Department

    RECRUITING

    Jacksonville, Florida, 32209, United States

  • UF Health Jacksonville North Emergency Department

    RECRUITING

    Jacksonville, Florida, 32218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.